Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solenopsis richteri
- Development stage
- Unknown
- Lead developer
- Greer Laboratories
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
Solenopsis richteri, commonly known as the black imported fire ant, is the biological source for allergenic extracts used in the diagnosis and treatment of fire ant sting hypersensitivity. These extracts, derived from the ant's venom or whole body, contain potent allergens such as Sol r 2 (a venom protein) and various piperidine alkaloids. Clinically, the extract is employed in skin prick or intradermal testing to identify IgE-mediated sensitivity and in subcutaneous immunotherapy (SCIT) to induce immunological tolerance. This desensitization process is critical for individuals at risk of systemic allergic reactions or anaphylaxis following stings. The venom of S. richteri exhibits significant allergenic cross-reactivity with that of the red imported fire ant (Solenopsis invicta), allowing for broad protection in regions where both species or their hybrids are prevalent.
- Other names
- Black imported fire antBIFA
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Solenopsis richteri.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solenopsis richteri.